Comparing Home Treatment Versus Hospitalization in Adults with Active Cancer and Stable Pulmonary Embolism Without HESTIA Criteria

What this Trial Is About

Researchers are evaluating home treatment compared to hospitalisation for patients with active cancer and either symptomatic or incidental pulmonary embolism PE who do not meet the HESTIA criteria. This study aims to show that treating these patients at home is not worse than hospital care regarding a combined measure of recurrent blood clots, bleeding events, and death within 14 days. The trial also looks at patient quality of life, treatment satisfaction, and healthcare costs to find the best approach for managing cancer-associated PE. Participants are randomly assigned to one of two groups. Those in the home-treatment group will be discharged within 24 hours after randomisation and receive phone follow-up within 7 days from the local thrombosis team. Those in the hospitalisation group will stay in the hospital for at least 48 hours after randomisation, after which doctors may discharge them. Anticoagulant treatment will be started promptly in both groups according to local protocols, and patients are advised to report any new symptoms or bleeding. Throughout the study, participants will be followed up at 7, 14, 30, and 90 days to monitor clinical events such as recurrent PE, bleeding, or death. Patient-reported outcomes including quality of life and treatment satisfaction will be collected using questionnaires. Data on healthcare resource use and costs will also be gathered. An independent committee blinded to treatment groups will evaluate all clinical endpoints to ensure unbiased assessment of safety and effectiveness.

Home Treatment of Patients With Active Cancer and Acute Pulmonary Embolism Without HESTIA Criteria.